Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$233.81 - $287.01 $33.3 Million - $40.8 Million
142,300 New
142,300 $39.1 Million
Q1 2024

May 09, 2024

BUY
$146.51 - $198.2 $424,879 - $574,780
2,900 New
2,900 $433,000
Q4 2021

Feb 10, 2022

SELL
$159.56 - $209.29 $670,152 - $879,018
-4,200 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$169.75 - $207.73 $6.52 Million - $7.98 Million
-38,400 Reduced 90.14%
4,200 $793,000
Q2 2021

Aug 12, 2021

BUY
$128.63 - $176.89 $3.55 Million - $4.88 Million
27,600 Added 184.0%
42,600 $7.22 Million
Q2 2020

Aug 12, 2020

SELL
$104.21 - $156.44 $739,891 - $1.11 Million
-7,100 Reduced 32.13%
15,000 $2.22 Million
Q1 2020

May 13, 2020

BUY
$93.12 - $133.99 $1.4 Million - $2.01 Million
15,000 Added 211.27%
22,100 $2.41 Million
Q4 2019

Feb 14, 2020

BUY
$74.51 - $124.23 $529,021 - $882,033
7,100 New
7,100 $818,000
Q2 2019

Aug 12, 2019

SELL
$65.86 - $92.79 $1.35 Million - $1.9 Million
-20,500 Closed
0 $0
Q1 2019

May 10, 2019

BUY
$72.76 - $93.45 $1.44 Million - $1.85 Million
19,800 Added 2828.57%
20,500 $1.92 Million
Q4 2018

Feb 13, 2019

SELL
$62.67 - $88.33 $56,403 - $79,497
-900 Reduced 56.25%
700 $51,000
Q3 2018

Nov 09, 2018

BUY
$87.52 - $122.67 $17,504 - $24,534
200 Added 14.29%
1,600 $140,000
Q2 2018

Aug 08, 2018

SELL
$88.31 - $107.8 $4.97 Million - $6.07 Million
-56,300 Reduced 97.57%
1,400 $138,000
Q1 2018

May 09, 2018

SELL
$115.92 - $148.54 $9.09 Million - $11.6 Million
-78,400 Reduced 57.6%
57,700 $6.87 Million
Q4 2017

Feb 09, 2018

BUY
$114.49 - $139.98 $7.13 Million - $8.72 Million
62,300 Added 84.42%
136,100 $17.3 Million
Q3 2017

Nov 13, 2017

BUY
$72.53 - $118.27 $5.35 Million - $8.73 Million
73,800
73,800 $8.67 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.